以岭药业：撤回“柴黄利胆胶囊”药品注册申请

Core Viewpoint - Yiling Pharmaceutical's subsidiary, Beijing Yiling, has withdrawn its drug registration application for "Chai Huang Li Dan Capsule" as per the notice from the National Medical Products Administration (NMPA) [1] Group 1: Drug Development and Registration - "Chai Huang Li Dan Capsule" is an innovative traditional Chinese medicine developed by the company, aimed at treating conditions such as chronic cholecystitis and gastrointestinal issues [1] - The new drug registration application was accepted by the NMPA in June 2024, indicating prior progress in the registration process [1] - The company plans to improve the registration materials according to the latest NMPA requirements and will resubmit the application promptly [1] Group 2: Impact on Business Operations - The withdrawal of the registration application is not expected to have a significant impact on the company's current and future operations and performance [1] - The company emphasizes the importance of drug research and development while maintaining strict control over R&D costs [1] - The company acknowledges the high risks and long cycles associated with drug development, highlighting the uncertainties involved [1]